<DOC>
	<DOCNO>NCT00382213</DOCNO>
	<brief_summary>The purpose study determine efficacy treatment olmesartan medoxomil , Angiotensin Receptor Blocker , compare placebo blood level surrogate marker vascular inflammation atherosclerotic disease . Patients randomize receive either olmesartan medoxomil placebo one year .</brief_summary>
	<brief_title>A Randomized , Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>Males Females age less equal 18 TEEdefined Grade III IV atherosclerotic disease thoracic aorta document within previous 90 day , establish atherosclerotic disease low extremity demonstrate : history low extremity peripheral vascular surgery obstructive atherosclerotic disease , history low extremity peripheral arterial angioplasty obstructive atherosclerotic disease , history low extremity amputation secondary atherosclerotic disease , ABI &lt; 0.90 within previous 90 day , history claudication patient document coronary artery disease ( i.e. , history myocardial infarction , coronary revascularization , coronary angiography demonstrate least one obstructive coronary lesion 50 % great stenosis ) . Women childbearing age agree utilize protocol approve contraceptive method . Average predose SBP &lt; 100 DBP &lt; 60 . Patients serious disorder include cardiovascular ( ventricular arrhythmia , valvular disease implantable defibrillator ) , renal , pulmonary , hepatic , gastrointestinal , endocrine/metabolic ( exclude patient control diabetes mellitus ) , hematologic/oncologic ( include active malignancy basal cell carcinoma nonmetastatic prostate cancer ) , neurologic , psychiatric disease . Patients history MI , PTCA , CABG , heart failure , CVA TIA within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>